Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

Keyphrases

• Patient Outcomes 100%
• Epithelial-mesenchymal Transition 100%
• Gene Amplification 100%
• Malignant Mesothelioma 100%
• Receptor Overexpression 100%
• Overexpression 13%
• Conventional Chemotherapy 8%
• Transition Protein 8%
• Reactive Mesothelial Proliferation 8%
• No Significant Difference 4%
• Immunohistochemistry 4%
• Malignancy 4%
• Lung Cancer 4%
• Response Rate 4%
• Therapeutic Target 4%
• Overall Survival 4%
• Progression-free Survival 4%
• Hybrid Method 4%
• Fluorescence in Situ Hybridization 4%
• Targeted Therapy 4%
• Overexpressing 4%
• Receptor Tyrosine Kinase 4%
• Low Response 4%
• Distinct Subtypes 4%
• Predictive Significance 4%
• Mesothelioma 4%
• Lung-other 4%
• Several Variables 4%
• Peritoneal Biopsy 4%
• Pleural Biopsy 4%
• Skipping mutations 4%
• Protein Upregulation 4%
• Gene Copy number Gain 4%
• Exon 14 Skipping 4%
• RNA Next Generation Sequencing 4%
• Pleurectomy 4%

Medicine and Dentistry

• Receptor 100%
• Mesenchymal-Epithelial Transition 100%
• Gene Amplification 100%
• Mesothelioma 100%
• Upregulation 8%
• Cancer 4%
• Lung Cancer 4%
• Immunohistochemistry 4%
• Overall Survival 4%
• Targeted Therapy 4%
• Fluorescence in Situ Hybridization 4%
• Protein Tyrosine Kinase 4%
• Progression Free Survival 4%
• Exon 4%
• Gene Dosage 4%
• Next Generation Sequencing 4%
• Peritoneal Biopsy 4%
• Pleura Biopsy 4%
• Pleurectomy 4%

Biochemistry, Genetics and Molecular Biology

• Eicosanoid Receptor 100%
• Mesenchymal-Epithelial Transition 100%
• Gene Amplification 100%
• Upregulation 8%
• Exon 4%
• Gene Dosage 4%
• Progression Free Survival 4%
• Overall Survival 4%
• RNA 4%
• Receptor Tyrosine Kinase 4%
• Fluorescence in Situ Hybridization 4%
• Next Generation Sequencing 4%